HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
GlobeNewswire
— Almost half a million people diagnosed each year across the globe —— Collaboration based on synergistic potential of..